摘要:
Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salts thereof, wherein: n1 and n2 are independently 0-2; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is alkyl or optionally substituted alkenyl; R22 is —COR23 or a carboxy, sulfinyl, sulfonyl, sulfonamide or amino acid derivative; R23 is haloalkyl; alkenyl; haloalkenyl; alkynyl; optionally substituted cycloalkyl; cycloalkyl-alkyl; aryl; arylalkyl; heteroaryl; heterocycloalkyl; or —COOH and/or —SO3H substituted alkyl; R1, R2, R3, R9, R10 and R11 are as defined in the specification; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.
摘要翻译:具有下式的杂环取代的三环或其药学上可接受的盐,其中:n 1和n 2个独立地为0-2; Het是任选取代的单,双或三环杂芳族基团; B是烷基或任选取代的烯基; R 22是-COR 23或羧基,亚磺酰基,磺酰基,磺酰胺或氨基酸衍生物; R 23是卤代烷基; 烯基; 卤代烯基 炔基; 任选取代的环烷基; 环烷基 - 烷基; 芳基; 芳烷基 杂芳基; 杂环烷基; 或-COOH和/或-SO 3 H取代的烷基; R 1,R 2,R 3,R 9,R 10和R 9, R 11如本说明书中所定义; 以及含有它们的药物组合物以及通过施用所述化合物治疗与血栓形成,动脉粥样硬化,再狭窄,高血压,心绞痛,心律失常,心力衰竭和癌症相关的疾病的方法。
摘要:
Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
摘要:
Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, cycloalkenyl, or heteroaryl; X is alkylene or —C(O)CH2—; Y is —N(R2)CH2CH2N(R)3)—, —OCH2CH2N(R2)—, —O—, —S—, —CH2S—, —(CH2)2—NH—, or optionally substituted m and n are 2-3, and Q is nitrogen or optionally substituted carbon; and Z is optionally substituted phenyl, phenylalkyl or heteroaryl, diphenylmethyl, R6—C(O)—, R6—SO2—, R6—OC(O)—, R7—N(R8)—C(O)—, R7—N(R8)—C(S)—, phenyl-CH(OH)—, or phenyl-C(═NOR2)—; or when Q is CH, phenylamino or pyridylamino; or Z and Y together are substituted piperidinyl or substituted phenyl; and R2, R3, R6, R7, and R8 are as defined in the specification are disclosed, their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them; also disclosed are a processes for preparing intermediates useful for preparing compounds of formula I.
摘要:
Antihypertensive and bronchodilating compounds of the formula or a pharmaceutically acceptable salt thereof, and a process for preparing them are disclosed, wherein:R.sub.1, R.sub.2, R.sub.3, R.sup.a, R.sup.b and R.sup.c as defined in the disclosure;pharmaceutical compositions containing said compounds;methods of treatment using said compounds; anda process for preparing polycyclic guanines comprisinga) reducing a nitrosopyrimidine, and treating the reduced nitrosopyrimidine with an acylating reagent to give the amidopyrimidine;b) reacting the amidopyrimidine with a halogenating/cyclizing reagent to give a halopurine;c) reacting, in the presence of a base, the halopurine with an amine to give the substituted aminopurine; andd) closing the ring of the substituted aminopurine with a suitable dehydrating agent.
摘要:
A system and method are provided for the reconstruction of medical image data using filtered backprojection with the use of a wavelet transformation. A filter function is applied to at least one part of an object using projection data captured with a detection device prior to backprojection.
摘要:
A system displays a raster-based or a vector-based formatted drawing on a user interface. A user selects a device on the drawing. The selected device is classified on a template. The drawing is searched for the classified template. Three-dimensional characteristics are imbued to the selected device. Connection types among different types of devices on the drawing are received into the system. A search is performed for all connection instances throughout the drawing using the received connection types. An object oriented and three-dimensionally, spatially referenced view of the drawing is generated on a user interface.
摘要:
A system displays a raster-based or a vector-based formatted drawing on a user interface. A user selects a device on the drawing. The selected device is classified on a template. The drawing is searched for the classified template. Three-dimensional characteristics are imbued to the selected device. Connection types among different types of devices on the drawing are received into the system. A search is performed for all connection instances throughout the drawing using the received connection types. An object oriented and three-dimensionally, spatially referenced view of the drawing is generated on a user interface.
摘要:
The present invention relates to a method for the synthesis of certain bridged fused ring pyridines. Such bridged fused ring pyridines can be converted to huperzine A and analogs of huperzine A. The present invention also covers such bridged fused ring pyridines, compounds utilized for the preparation of the bridged fused ring pyridines and analogs of huperzine A.
摘要:
The present invention relates to a method for the synthesis of certain bridged fused ring pyridines. Such bridged fused ring pyridines can be converted to huperzine A and analogs of huperzine A. The present invention also covers such bridged fused ring pyridines, compounds utilized for the preparation of the bridged fused ring pyridines and analogs of huperzine A. The compounds are capable of inhibiting cholinesterase enzymes and, therefore, are useful as pharmaceutical agents for treatment of disorders involving cholinesterase enzymes. Examples of such disorders include myasthenia gravis, Alzheimer's dementia and the improvement of senile memory loss.
摘要:
The present invention relates to a method for the synthesis of certain bridged fused ring pyridines. Such bridged fused ring pyridines can be converted to huperzine A and analogs of huperzine A. The present invention also covers such bridged fused ring pyridines, compounds utilized for the preparation of the bridged fused ring pyridines and analogs of huperzine A.